ATLANTA--(BUSINESS WIRE)-- Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell Plumb, president and chief executive officer, will present an overview of the Company and an update of its pipeline of differentiated antiviral compounds at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference on February 16, 2011 at 3:20 PM (EST). The conference is being held at The Roosevelt Hotel in New York, NY. The presentation will be simultaneously webcast and can be accessed by visiting the Investors section of the Inhibitex website at www.inhibitex.com. Shortly following the live webcast, a replay will also be available on the Company website.
About Inhibitex
Inhibitex, Inc., is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company’s clinical-stage pipeline includes FV-100, a nucleoside inhibitor in Phase II for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in Phase 1b for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of staphylococcal vaccines. For additional information about the Company, please visit www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.
CONTACT:
Inhibitex, Inc.
Russell H. Plumb, 678-746-1136
Chief Executive Officer
[email protected]
or
The Trout Group
Lee M. Stern, 646-378-2922
[email protected]
KEYWORDS: United States North America Georgia New York
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Hospitals Infectious Diseases Pharmaceutical Research Science
MEDIA:
| Logo |